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 Abstract 
 
The PTEN gene encodes a master regulator protein that exerts essential functions both 
in the cytoplasm and in the nucleus. PTEN is mutated in the germline of both patients 
with heterogeneous tumor syndromic diseases, categorized as PTEN Hamartoma Tumor 
Syndrome (PHTS), and a group affected with Autism Spectrum Disorders (ASD). 
Previous studies have unveiled the functional heterogeneity of PTEN variants found in 
both patient cohorts, making functional studies necessary to provide mechanistic 
insights related to their pathogenicity. Here, we have functionally characterized a PTEN 
missense variant [c.49C>G; p.(Gln17Glu); Q17E] associated to both PHTS and ASD 
patients. The PTEN Q17E variant displayed partially reduced PIP3-catalytic activity 
and normal stability in cells, as shown using S. cerevisiae and mammalian cell 
experimental models. Remarkably, PTEN Q17E accumulated in the nucleus, in a 
process involving the PTEN N-terminal nuclear localization sequence. The analysis of 
additional germline-associated PTEN N-terminal variants illustrated the existence of a 
PTEN N-terminal region whose targeting in disease causes PTEN nuclear accumulation, 
in parallel with defects in PIP3-catalytic activity in cells. Our findings highlight the 
frequent occurrence of PTEN gene mutations targeting PTEN N-terminus whose 
pathogenicity may be related, at least in part, with the retention of PTEN in the nucleus. 
This could be important for the implementation of precision therapies for patients with 
alterations in the PTEN pathway. 
 
Keywords: PTEN, PHTS, ASD  
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Introduction 
 
The PTEN gene encodes a phosphatase whose major activity is the dephosphorylation 
of phosphatidylinositol 3,4,5-trisphosphate (PIP3) to render phosphatidylinositol 4,5-
bisphosphate (PIP2). This enzymatic activity counteracts the action of class I 
phosphatidylinositol 3-kinases (PI3K), thus negatively regulating the PI3K/AKT/mTOR 
pro-survival signaling pathway 1-3. PTEN also dephosphorylates a wide array of 
proteins, some of which are related with the regulation of cell motility and migration 4. 
In addition, PTEN possesses catalysis-independent activities, mainly mediated by 
protein-protein interactions 5. Both, catalysis-dependent and -independent activities are 
associated with specific PTEN subcellular compartmentation. In particular, cytoplasmic 
localization and transient binding of PTEN to membranes is related with the 
dephosphorylation of PIP3, whereas PTEN nuclear localization is mostly associated 
with transcriptional regulation and DNA damage control mediated by protein-protein 
interactions 6-9. The regulated intracellular shuttling of PTEN involves several 
molecular determinants in the PTEN protein, which include, among others, a cluster of 
phosphorylatable amino acids at PTEN C-terminal tail and a set of overlapping 
subcellular localization motifs at PTEN N-terminus (NLMs, N-terminal localization 
motifs)10-12. Conformational changes in the PTEN protein that expose these motifs to 
targeting or anchoring moieties regulate PTEN catalytic activity and subcellular 
distribution in cells 8,13-16. 
 
The PTEN gene is the second tumor suppressor, after TP53, in terms of somatic 
mutation frequency in human tumors. PTEN is also mutated in the germline of patients 
with syndromic predisposition to several types of cancer, grouped as PHTS (PTEN 
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Hamartoma Tumor Syndrome) 17. In addition, the PTEN gene is mutated in up to 15% 
of Autism Spectrum Disroders (ASD) patients with macrocephaly, and other genes 
directly related with the PI3K/AKT/mTOR pathway, including the PIK3CA, PIK3R1, 
AKT1, and AKT3 protooncogenes, have also been found mutated in the germline of 
patients with tumor predisposition or with megalencephaly-related disorders 18-22. This 
is in line with an important contribution for the effectors of the PI3K/AKT/mTOR 
pathway not only in tissue oncogenesis, but also in brain growth and development 23,24. 
In ASD patients, PTEN variants generated by missense mutations are prevalent, and 
although their functional impact in terms of PTEN catalytic activity is variable, many of 
these variants do not show severe intrinsic impaired catalytic activity but display 
diminished protein stability 25-27. Intriguingly, several missense germline mutations at 
PTEN have been found on both PHTS and ASD patients, indicating a heterogeneous 
penetrance for these mutations, which could be due in part to PTEN functional 
alterations which go beyond its catalytic activity. In this study, we have functionally 
characterized a PTEN variant found on both PHTS and ASD patients, [c.49C>G; 
p.(Gln17Glu); Q17E]. The PTEN Q17E variant retained most of PTEN stability and 
catalytic activity, but displayed abnormal subcellular localization, being enriched in the 
cell nucleus. Further analysis unveiled that disease-associated variants displaying amino 
acid substitutions PTEN N-terminus frequently cause both PTEN nuclear accumulation 
and defects in PTEN catalytic activity in cells. Our findings suggest that misregulated 
PTEN nuclear accumulation could be related, at least in part, with the pathogenicity of a 
group of disease-associated PTEN variants. 
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Materials and Methods 
 
Cell Culture, Transfections, Plasmids, and Mutagenesis 
Simian kidney COS-7 cells were grown in DMEM containing high glucose 
supplemented with 5% heat-inactivated fetal bovine serum (FBS), 1 mM L-glutamine, 
100 U/ml penicillin, and 0.1 mg/ml streptomycin. Human glioblastoma U87MG cells 
were grown in DMEM containing high glucose supplemented with 10% heat-
inactivated FBS, 1 mM L-glutamine, 1 mM sodium pyruvate, 1% non-essential amino 
acids, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Cells were grown at 37° C, 5% 
CO2. Cells were transfected by the DEAE-dextran method (COS-7 cells) or using 
Lipofectamine (ThermoFisher Scientific, USA) (U87MG cells), and processed after 48 
h. For experiments of protein stability, cells were treated with 800 µg/mL 
cycloheximide (SigmaAldrich) for 6 h before lysis. The Saccharomyces cerevisiae 
strain YPH499 (MATa ade2-101 trp1-63 leu2-1 ura3-52 his3-∆200 lys2-801) was used 
for heterologous expression of mammalian proteins. YPH499 yeast cells were grown in 
synthetic complete (SC) medium, containing 0.17 % yeast nitrogen base without amino 
acids, 0.5 % ammonium sulfate supplemented with appropriate amino acids and nucleic 
acid bases, and added 2 % glucose (SD), galactose (SG) or raffinose (SR), as required. 
Yeasts were transformed by standard procedures, and drop growth assays and GFP-
AKT1 distribution analyses were performed as described 12,28,29. pRK5 PTEN, pSG5 
AKT1, pYES2 PTEN, and YCpLG myc-p110α-CAAX plasmids have been previously 
described 10,28. The pRK5 PTEN-GFP (C-terminal tagging) plasmid was made by PCR 
and subcloning into pRK5. The PTEN and PTEN-GFP amino acid substitution variants 
were made by PCR oligonucleotide site-directed mutagenesis as described 30, and 
mutations were confirmed by DNA sequencing. Nucleotide and amino acid numbering 
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for PTEN variants correspond to reference sequences from accession numbers 
NM_000314.4 and NP_000305.3, respectively. Nomenclature of variants is according 
to ref 31. Variants and phenotypes data have been deposited in the LOVD gene variant 
database (http://www.lovd.nl/3.0/home) 32, with the following accession IDs: 
https://databases.lovd.nl/shared/variants/0000351723,  
0000352569-0000352584, 0000352586-0000352590, and 0000353018. 
 
Immunofluorescence and microscopy techniques 
PTEN subcellular location in COS-7 cells immunofluorescence was determined by 
immunofluorescence as previously described, using mouse monoclonal anti-PTEN 
425A and fluorescein-conjugated anti-mouse antibody 12,33. PTEN-GFP (Green 
Fluorescence Protein) subcellular location in COS-7 cells was directly visualized by 
standard fluorescence microscopy. For quantitation of PTEN subcellular distribution, at 
least 50 positive cells were scored for each experiment. Cells were rated as showing 
nuclear staining (N), cytoplasmic staining (C), or staining within both the nucleus and 
the cytoplasm (N/C). Nuclei were identified by DAPI (Sigma-Aldrich, USA) staining. 
All pictures were taken under a 20X magnification. Measurement of GFP-AKT1 plasma 
membrane localization in yeast, as an indirect indicator of cellular PIP3 levels, was 
performed by fluorescence microscopy, as described 12,28. ≥100 cells were examined 
and scored for each condition or experiment for either cytoplasmic or membrane-
associated localization. 
 
Immunoblotting 
Whole cell protein extracts from COS-7 and U87MG cells overexpressing ectopic 
PTEN variants were prepared by cell lysis in ice-cold M-PERTM lysis buffer 
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(ThermoFisher Scientific) supplemented with PhosSTOP phosphatase inhibitor and 
cOmplete protease inhibitor cocktails (Roche, Switzerland), followed by centrifugation 
at 15200 g for 10 min and collection of the supernatant. Proteins (50-100 µg) were 
resolved in 10% SDS-PAGE under reducing conditions and transferred to PVDF 
membranes. Immunoblotting was performed using anti-phospho-Ser473-AKT and anti-
AKT (Cell Signaling Technologies, USA), anti-PTEN 6H2.1 (Merck Millipore, USA), 
or anti-GAPDH (Santa Cruz Biotechnology, USA) antibodies, followed by horseradish 
peroxidase (HRP)-conjugated anti-rabbit or anti-mouse (Calbiochem, USA) antibodies. 
For determination of phospho-AKT content and PTEN protein stability, bands were 
quantified using an Image studioTM software with Odyssey® CLx Imaging System (LI-
COR, USA). 
 
 
Results and Discussion 
 
The PTEN Q17E variant targets the PTEN N-terminal localization motifs 
The PTEN Q17E mutational variant [c.49C>G; p.(Gln17Glu)] has been reported both in 
PHTS and ASD patients 34,35, suggesting a relevant functional impact on PTEN 
function. The PTEN residue Gln17 (Q17) is located within the PTEN N-terminal 
localization motifs (NLMs) of the PTEN PTP domain, which include a PIP2 binding 
motif (PBM, residues 6-15) 36, a nuclear localization signal (NLS, residues 8-32) 10, and 
a cytoplasmic localization signal (CLS, residues 19-25) 37. As with other amino acids in 
this region, Q17 is well conserved among species, although in the fly D. melanogaster a 
Lys (K) is present in the equivalent position (Fig. 1A). This suggests that Q17 is 
important, but not essential, for PTEN function. The PTEN NLMs are surface-exposed, 
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which facilitates their interaction with targeting or regulatory moieties, and they show 
the same topological orientation with the positively-charged TI-loop at the PTEN PTP 
domain, as well as the CBR3- and Cα2-membrane-binding loops at the C2 domain 
(Fig.1B) 8,38,39. Together, these observations suggest a role for Q17 in regulation of the 
function and the subcellular partitioning of PTEN. 
 
The PTEN Q17E variant displays slightly reduced PIP3-phosphatase activity and 
is stable in cells 
We have previously shown that a PTEN Q17A experimental variant [c.(49C>G; 
50A>C); p.(Gln17Ala)] slightly affects the PIP3-phosphatase activity of PTEN in a 
heterologous yeast system without affecting PTEN cytoplasm/nuclear distribution 12. 
Here, we have analyzed, both in yeast and in mammalian cells transfected with the 
appropriate cDNAs, the functionality of the PTEN Q17E variant, in comparison with 
variants Q17A and Q17P [c.50A>C; p.(Gln17Pro)] (associated to a glioma tumor 
sample; cancer.sanger.ac.uk/cosmic). The PTEN Q17E variant displayed lower PIP3-
phosphatase activity when compared with wild type PTEN, both in yeast (Fig.2A and 
B) and in mammalian cells (Fig. 2C), although in the case of mammalian cells the 
difference was not statistically significant. A similar effect was observed upon 
transfection of COS-7 PTEN-positive cells and U87MG PTEN-negative cells. 
Contrarily, PTEN Q17P behaved as a full loss-of-function PTEN variant, like the 
catalytically inactive PTEN C124S variant [c.371G>C; p.(Cys124Ser)], in both 
experimental settings (Fig. 2). Thus, we conclude that the PTEN Q17E variant is only 
partially affected in its in vivo catalytic activity. These results are in agreement with 
those reported by Nguyen et al., showing a similar in vitro PIP3-phosphatase activity for 
PTEN Q17E and PTEN wild type 40.  
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 The ASD-associated PTEN variants frequently cause destabilization and degradation of 
the PTEN protein 25,27. Next, we analyzed the protein stability of the PTEN Q17E 
variant in transfected mammalian COS-7 and U87MG cells by measuring protein 
degradation in the presence of the protein synthesis inhibitor cycloheximide, in 
comparison with the unstable PTEN D252G variant [c.755A>G; p.(Asp252Gly)] (also 
found in ASD and PTHS patients) 27. As shown, PTEN Q17E protein stability was 
similar to that of PTEN wild type, and higher to that displayed by PTEN D252G (Fig. 
3). Thus, different to other PTEN variants associated to disease (such as Q17P or 
D252G), that strongly affect PTEN catalysis or protein stability, the PTEN Q17E 
variant displayed slightly diminished PIP3-phosphatase activity and normal protein 
stability in cells. Interestingly, the Q17E variant has not been reported up to date in 
cancer somatic mutation databases, such as COSMIC or cBioPortal (Supplementary 
Table 1, and data not shown). 
 
The PTEN Q17E variant accumulates in the nucleus 
Next, we assessed the subcellular distribution of PTEN Q17E, in comparison with 
PTEN wild type, PTEN Q17A, and PTEN Q17P. Immunofluorescence analysis in 
transfected COS-7 cells revealed that PTEN Q17E, but not PTEN wild type or Q17A 
accumulated in the nucleus (Fig. 4A). Remarkably, the glioma-associated PTEN Q17P 
variant also displayed increased nuclear accumulation, unveiling a crucial role for the 
Q17 residue in the control of PTEN nucleus-cytoplasm shuttling. As shown in Fig. 4A, 
a PTEN K13A experimental variant [c.(37A>G; 38A>C); p.(Lys13Ala)] with a non-
functional N-terminal NLS 10,12, did not show these changes, demonstrating the 
involvement of the N-terminal NLS in the nuclear accumulation of the PTEN Q17E and 
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Q17P variants. When a PTEN-GFP protein was used to monitor PTEN subcellular 
localization in transfected COS-7 cells, the nuclear accumulation of PTEN Q17E and 
Q17P was also observed, and was dependent on the integrity on the N-terminal PTEN 
NLS as well (Fig. 4B). This is in agreement with the observation that a PTEN-GFP 
Q17E variant is modestly accumulated in the nucleus of D. discoideum cells 40. 
Mutation of the PTEN catalytic Cys (PTEN C124S variant) had no effect on the 
subcellular distribution of PTEN Q17E or Q17P, indicating that the nuclear 
accumulation of these PTEN variants is independent of PTEN catalysis (Fig. 4B). 
 
Germline-associated variants targeting the PTEN N-terminus cause PTEN nuclear 
accumulation 
Next, we analyzed the subcellular localization of the complete set of N-terminal PTEN 
variants, expanding residues 12-32, found in the germline of PHTS or ASD patients, 
using PTEN-GFP as the reporter (Supplementary Table 1). As shown, nuclear 
accumulation was prominent on disease-associated variants targeting residues 17 to 26 
(Fig. 5A; Supplementary Table 1). This is in agreement with the findings by Denning et 
al., which proposes the existence of a CLS at this PTEN region 37. Alternatively, the 17-
26 PTEN region could behave as a nuclear exclusion motif, as proposed for regions at 
the TI-, CBR3-, and Cα2-loops 8,10, which hampers the exposure of the overlapping 
atypical NLS motif at residues 8-32. Interestingly, the PTEN PBM overlaps with the 
NLS (see Fig. 1A), and it has been proposed a dynamic and cooperative role for the 
PBM and TI-loop at the PTP domain, as well as the CBR3- and Cα2-loops at the C2 
domain, for PTEN plasma membrane binding and activation 38,41,42. Thus, the exposed 
loop at the N-terminal NLMs PTEN region (Fig. 1B) could work as a PTEN 
conformational sensor regulating both PTEN subcellular localization and lipid 
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phosphatase activity. In our experiments, the PIP3 in vivo functional analysis showed a 
partial or total loss-of-function phenotype for most variants at the 17-26 region (Fig. 
5B; Supplementary Table 1), suggesting a link between a defective catalytic activity in 
cells and aberrant nuclear accumulation. Our results argue that mutations affecting 
PTEN function and targeting the PTEN N-terminal region frequently favor PTEN 
nuclear accumulation in parallel with decreasing PTEN PIP3 phosphatase activity in 
cells. This suggests that PTEN nuclear accumulation could be a surrogate marker for 
loss of PIP3 phosphatase activity in some patients carrying PTEN N-terminal variants. 
In addition, N-terminal mutated nuclear PTEN could also manifest a dysfunctional role 
independently of its catalysis, in line with the nuclear retention of PTEN found in some 
tumors or in cells from some PHTS patients 43,44. In this regard, some PHTS-associated 
PTEN variants that target PTEN at other regions display nuclear accumulation in 
association with p53 downregulation and increased DNA damage 45,46. Further work is 
required to elucidate the nuclear mechanisms by which N-terminal mutated nuclear 
PTEN may be causative of PTEN-associated disease. This could shed some light on the 
variable qualitative penetrance of specific PTEN gene mutations found on both PHTS 
and ASD patients. 
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Figure legends 
 
Figure 1. Localization and species conservation of Gln17 (Q17) residue in PTEN 
protein. A. At the top, the human PTEN amino acid sequence (single-letter amino acid 
code) (accession number NP_000305.3) from residues 1-32 is shown, indicating the 
PTEN N-terminal localization motifs (NLMs): nuclear localization signal (NLS), PIP2-
binding motif (PBM), and cytoplasmic localization signal (CLS). Residue Q17 is 
indicated with an arrow. At the bottom, an alignment of PTEN N-terminal amino acid 
sequence from different species is shown. Conserved residues are shadowed. Note that 
D. rerio possesses two PTEN-like genes. Numbers in brackets correspond to amino acid 
numbering. B. Depiction of localization of Q17 residue in the PTEN 3D structure 
(accesion ID5R). Residues Q17 and Thr26 (T26) are indicated with an arrow. The 
localization of the TI-, Cα2-, and CBR3-membrane-binding loops is also indicated. 
PTP, protein tyrosine phosphatase domain; C2, C2-membrane binding domain. 
 
 
Figure 2. Functional activity of PTEN Q17E variant in cells. A and B. Functional 
activity of PTEN Q17E variant in a heterologous yeast S. cerevisiae system. In A, a 
yeast growth drop assay is shown of cells transformed with different combinations of 
plasmids encoding a hyperactive form of the mammalian PI3K p110α catalytic subunit 
(p110α-CAAX) and PTEN variants, under glucose growth conditions (control, no 
induction of heterologous proteins) or galactose growth conditions (induction of 
heterologous proteins). The growth of yeast cells is inhibited by PI3K (PI3K+vector), 
which converts essential pools of PIP2 into PIP3. This can be prevented by the 
expression of active PTEN [PI3K+PTEN wild type (WT)] but not catalytically inactive 
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PTEN mutation (PI3K+PTEN C124S). PTEN Q17E partially rescued the effect of 
PI3K. In B, the activity of PTEN variants was quantified co-transforming the yeast with 
plasmids encoding a GFP-AKT1 reporter, which binds to PIP3 at the plasma membrane. 
Monitored microscopically, removal of the GFP-AKT1 reporter form the plasma 
membrane is a read-out of PTEN activity on PI3K-generated PIP3 substrate. Data are 
the average of three experiments on three different clones (n>100 cells per clone). Bars 
correspond to the standard deviation + SD. Student’s t-test P-values are shown. C. 
Functional activity of PTEN Q17E variant in mammalian cells. COS-7 or U87MG cells 
were co-transfected with different combinations of plasmids encoding AKT1 and PTEN 
variants (WT, PTEN wild type), and the phosphorylation of AKT (as an indirect 
measurement of PTEN catalytic activity) was monitored by immunoblotting using anti-
pAKT (Ser473) antibody. The expression of total AKT, PTEN, and GAPDH (as a 
loading control) was also monitored using specific antibodies. In the top panels, 
representative experiments are shown. In the bottom panels, the pAKT/AKT ratio from 
each condition is shown, after quantification of the bands from at least three 
independent experiments. Student’s t-test P-values are shown. Note the slight decrease 
(statistically non-significant) in PTEN Q17E activity when compared with PTEN wild 
type. 
 
 
Fig. 3. Stability of PTEN Q17E in cells. COS-7 or U87MG cells were transfected with 
pRK5 plasmids encoding the indicated PTEN variants (WT, wild type), and cells were 
incubated in the presence of cycloheximide (CHX) for 6 h to monitor protein 
degradation. PTEN protein levels were measured by immunoblotting using anti-PTEN 
antibody. GAPDH is shown as loading control. In the top panels, representative 
16 
 
experiments are shown. In the bottom panels, the PTEN protein levels after 
cycloheximide cell treatment are shown as the ratio 6 h/0 h + SD, after quantification of 
the bands from at least three independent experiments. Student’s t-test P-values are 
shown. PTEN Q17E displayed similar stability than PTEN wild type. 
 
 
Figure 4. Subcellular localization of PTEN Q17E. A. COS-7 cells were transfected with 
pRK5 plasmids encoding the indicated PTEN variants, and cells were analyzed by 
immunofluorescence using anti-PTEN antibody. In the top panels, representative 
images are shown. In the bottom panels, quantification of percentages of cells with 
nuclear (N), cytoplasmic (C), or nuclear/cytoplasmic (N/C) localization is shown. B. 
COS-7 cells were transfected with plasmids encoding the indicated PTEN-GFP variants 
(C-terminal tagging) (WT, wild type) and analyzed by fluorescence microscopy. In the 
top panels, representative images are shown. In the bottom panels, quantification of 
percentages of cells with nuclear (N), cytoplasmic (C), or nuclear/cytoplasmic (N/C) 
localization is shown.  
 
 
Figure 5. Functional analysis of PTEN N-terminal germline mutations. A. COS-7 cells 
were transfected with plasmids encoding the indicated PTEN mutations (WT, wild 
type), in the background of PTEN-GFP, and cells were analyzed by fluorescence 
microscopy. Quantification of percentages of cells with nuclear (N), cytoplasmic (C), or 
nuclear/cytoplasmic (N/C) localization is shown. B. In vivo PTEN activity in the yeast 
heterologous model. Yeast cells were co-transformed with plasmids encoding p110α-
CAAX, GFP-AKT1, and the indicated PTEN variants (WT, wild type), and PIP3-
17 
 
phosphatase activity was assessed as in Fig. 2. The percentage of cells with GFP-AKT1 
in the cytoplasm (C), indicative of PTEN PIP3 phosphatase activity, or in the plasma 
membrane (PM), within the population of transformant clones co-expressing p110α-
CAAX, GFP-AKT1 and the respective PTEN variants, is represented. Data are the 
average of three experiments on three different clones (n>100 cells per clone).  
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 Table 1. Functional analysis of PTEN N-terminal germline missense variants 
Variants1 Amino acid substitution2 Disease
3 Age of diagnosis4 
Reported in databases5 Subcellular 
location6 
PIP3 in vivo 
activity7 Reference
8 
HGMD COSMIC ClinVar 
Wild type Wild type      N/C +  
c.35A>C p.(Asp12Thr) / N12T ASD 5.2 y + - + N/C + 1 
c.35A>T p.(Asp12Ile) / N12I CS nr + - - N/C - 2 
c.37A>G p.(Lys13Glu) / K13E CS nr + + - C - 3 
c.40A>G p.(Arg14Gly) / R14G ASD 3.3 y + + + N/C - 1 
c.45A>T p.(Arg15Ser) / R15S CS ASD 
nr 
18 m + + + N/C - 
4 
5 
c.46T>C p.(Tyr16His) / Y16H PHTS nr + - + N/C + 6 
c.49C>G p.(Gln17Glu) / Q17E CS ASD 
nr 
10 m + - + N +/- 
2 
5 
c.65A>G p.(Asp22Gly) / D22G CS;BRRS nr + + + N - 7 
c.66C>G p.(Asp22Glu) / D22E ASD nr - + - N +/- 8 
c.67T>G p.(Leu23Val) / L23V CS nr + + - N - 2 
c.69A>C p.(Leu23Phe) / L23F CS nr + + - N +/- 2 
c.70G>C p.(Asp24His) / D24H CS 65.4 y + + + N - 9 
c.70G>T p.(Asp24Tyr) / D24Y BRRS;DD 4 + + + N - 10 
c.71A>G p.(Asp24Gly) / D24G PHTS 57.7 y; 36.8 y; 6.7 y + + + N - 9 
c.71A>T p.(Asp24Val) / D24V CS 39 + + - N - 11 
Table 1 (cont.). Functional analysis of PTEN N-terminal germline missense variants 
Variants1 Amino acid substitution2 Disease
3 Age of diagnosis4 
Reported in databases5 Subcellular 
location6 
PIP3 in vivo 
activity7 Reference
8 
HGMD COSMIC ClinVar 
c.75G>T p.(Leu25Phe) / L25F CS ASD 
9.6 y 
7 y + + - N - 
9
12 
c.76A>C p.(Thr26Pro) / T26P CS nr 25.7 y; 19 y + + - N - 
4 
9 
c.77C>T p.(Thr26Ile) / T26I DD;macroc 12 m + - - N +/- 13 
c.80A>G p.(Tyr27Cys) / Y27C ASD 10 m + + + N/C - 5 
c.79T>A p.(Tyr27Asn) / Y27N PHTS nr + + - N/C - 6 
c.89C>T p.(Pro30Leu) / P30L CS nr + - - N/C + 3 
c.95T>A p.(Ile32Asn) / I32N CS nr 56.4 y + - - N/C - 
4 
9
 
 1PTEN germline variants at residues 12-32 are listed. Nucleotide and amino acid numbering corresponds to accessions NM_000314.4 and NP_000305.3, 
respectively. 
 2Amino acid substitutions are indicated following HGVS recommended nomenclature, as well as with single-letter code amino acid nomenclature. 
 3As reported in the indicated reference. ASD, autism spectrum disorder; BRRS, Bannayan-Riley-Ruvalcaba syndrome; CS, Cowden syndrome; DD, developmental 
delay; macroc, macrocephaly; PHTS, PTEN hamartoma tumor syndrome. 
 4As reported in the indicated reference. Note that in some cases there is information on more than one patient. nr, not reported; y, years; m, months. 
 5HGMD, Human Gene Mutation Database (Professional) (QIAGENBIOINFORMATICS) 14; COSMIC, Catalogue of Somatic Mutations in Cancer (Wellcome Trust 
Sanger Institute) 15; ClinVar (NCBI) 16. 
 6As determined by fluorescence microscopy in mammalian cells using PTEN-GFP (Fig. 5A). The major location is indicated: N, nuclear location; N/C, 
nuclear/cytoplasmic location; C, cytoplasmic location. 
 7As determined by GFP-AKT1 reporter assays in yeast (Fig. 5B): +, full activity (0-24% PIP3(+) cells); +/-, partial activity (25-74% PIP3(+) cells); -, no activity (75-100% 
PIP3(+) cells). +, full activity (75-100% PIP3(-) cells); +/-, partial activity (25-74% PIP3(-) cells); -, no activity (0-24% PIP3(-) cells). Note that the changes in PIP3 
phosphatase activity of the PTEN Q17E variant in mammalian cells were not statistically significant (Fig. 2C), when compared to PTEN wild type. 
 8Original references (to the best of our knowledge) for mutation-encoding variants from patients are provided. In some cases, additional references are provided which 
contain information on the patient age of diagnosis. 
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